Illumina Inc (ILMN)vsNatera Inc (NTRA)
ILMN
Illumina Inc
$288.79
+3.33%
HEALTHCARE · Cap: $39.64B
NTRA
Natera Inc
$424.42
+3.31%
HEALTHCARE · Cap: $58.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Illumina Inc generates 66% more annual revenue ($4.49B vs $2.71B). ILMN leads profitability with a 18.3% profit margin vs -7.1%. ILMN earns a higher WallStSmart Score of 51/100 (C-).
ILMN
Buy51
out of 100
Grade: C-
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+58.2%
Fair Value
$278.38
Current Price
$288.79
$10.41 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 29 in profit
Strong operational efficiency at 21.1%
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 15.4x book value
Grey zone — moderate risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.0% earnings growth
Weak financial health signals
Trading at 33.5x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ILMN
The strongest argument for ILMN centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 21.1%.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Market Cap, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : ILMN
The primary concerns for ILMN are Price/Book, Altman Z-Score, PEG Ratio. A P/E of 49.0x leaves little room for execution misses.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ILMN profiles as a mature stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.50 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
ILMN generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
ILMN scores higher overall (51/100 vs 31/100), backed by strong 18.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Illumina Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?